<DOC>
	<DOCNO>NCT01207765</DOCNO>
	<brief_summary>The study involve use targeted form radiation , addition standard high dose chemotherapy stem cell transplant multiple myeloma . The use target radiation design kill multiple myeloma cell avoid side effect standard radiation . This type target radiation ( also know radioimmunotherapy ) approve Food Drug Administration ( FDA ) treatment related disease , lymphoma trade name , Zevalin© . Zevalin© add high dose chemotherapy stem cell transplant patient lymphoma studied clinical trial patient multiple myeloma . This trial available Tufts Medical Center . The proposed clinical trial test whether CD20-targeted radio-immunotherapy safe effective integrate standard regimen myeloablative chemotherapy autologous stem cell rescue patient measurable disease prior high dose chemotherapy autologous stem cell transplant multiple myeloma .</brief_summary>
	<brief_title>Zevalin Patients With Incomplete Response Chemo Prior Autologous Stem Cell Transplant Multiple Myeloma</brief_title>
	<detailed_description>Patients multiple myeloma schedule standard care high dose melphalan autologous stem cell transplant incomplete response induction treatment ( i.e . measurable disease ) follow peripheral blood stem cell collection candidate participation trial . 90Y Zevalin target CD20 express surface mature B-cells FDA approve relapsed/refractory low grade lymphoma . This single arm , phase II safety efficacy study 90-Y Zevalin multiple myeloma . Subjects receive cold antibody ( Rituximab 100mg/m2 ) follow 5 mCi test dose 111-In Zevalin transplant day -21 . Gamma camera image obtain 48 72 hour 111-In Zevalin document appropriate / expect distribution radiotracer . On transplant day -14 , subject receive another cold antibody dose follow 90Y Zevalin 0.4 mg/kg ( max 32 mCi ) single dose . Subjects admit transplant day -3 proceed institution standard high dose melphalan ( 200mg/m2 ) day -2 . Subjects follow safety 6 week transplant .</detailed_description>
	<mesh_term>Multiple Myeloma</mesh_term>
	<mesh_term>Neoplasms , Plasma Cell</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<criteria>Meet establish criterion diagnosis multiple myeloma DurieSalmon stage II III disease Measurable disease serum and/or urine Scheduled receive high dose chemotherapy autologous stem cell transplant multiple myeloma Individuals previously undergone autologous stem cell transplant eligible study provide 6 month elapse prior transplant . Minimum stem cell dose 4x106 CD34+ MNC / kg store autologous stem cell rescue . Adequate hematologic reserve evidence ANC ≥ 1500/mm3 platelet ≥ 100,000/mm3 . Serum direct bilirubin ≤ 2.0 mg/dl transaminase ≤ 3x institution upper limit normal . Serum creatinine ≤ 2 mg/dl creatinine clearance ≥ 60 ml/min ( either calculate measure ) . Stage I smolder myeloma , isolated plasmacytoma , benign monoclonal gammopathy Nonsecretory multiple myeloma Pregnant lactate woman Males female agree practice approve method birth control duration study Presence active infection Receipt previous radiation therapy critical organ exceed follow limit : kidney 500 cGy , liver 1000 cGy , lungs 500 cGy</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>Multiple Myeloma</keyword>
	<keyword>Zevalin</keyword>
</DOC>